Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fintel reports that on May 24, 2023, Goldman Sachs maintained coverage of Agilent Technologies (NYSE:A) with a Buy recommendation.

Goldman Sachs Maintains Agilent Technologies Buy Recommendation

Agilent Technologies' (A) second-quarter fiscal 2023 results reflect strength across LSAG and ACG segments.

Agilent (A) Q2 Earnings Match Estimates, Revenues Rise Y/Y

Agilent topped Wall Street's consensus earnings estimate in its latest quarter. However, market uncertainties caused the company to provide weaker-than-expected guidance.

Why Agilent Technologies Stock Is Sinking Today

Agilent Technologies (NYSE:A) Inc stock tumbled after it cut its outlook for its fiscal year 2023 while noting that demand from biotech companies had dried up in the difficult environment. “We expect this constrained capital environment to remain in place throughout the course of our fiscal year.

Agilent Technologies stock tumbles after it lowers outlook for its fiscal year

The laboratory instruments maker posted earnings of $1.27 per share, better than the $1.26 expected by analysts.

Agilent Gets a Downgrade After Strong Earnings. Here's Why.

Agilent Technologies, Inc. (NYSE:A ) Q2 2023 Earnings Conference Call May 23, 2023 4:30 PM ET Company Participants Parmeet Ahuja - IR Mike McMullen - President and CEO Robert McMahon - SVP and CFO Padraig McDonnell - President, Agilent CrossLab Group Sam Raha - President, Agilent Diagnostics & Genomics Group Jacob Thaysen - President, Agilent Life Science & Applied Markets Group Conference Call Participants Brandon Couillard - Jefferies Vijay Kumar - Evercore ISI Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Dan Leonard - Credit Suisse Mike Ryskin - Bank of America Dan Brennan - TD Cowen Jack Meehan - Nephron Patrick Donnelly - Citi Josh Waldman - Cleveland Research Liza Garcia - UBS Operator Ladies and gentlemen, welcome to the Agilent Technologies' Q2 2023 Earnings Call. My name is Sarah, and I will be coordinating your call today.

Agilent Technologies, Inc. (A) Q2 2023 Earnings Call Transcript

Agilent Technologies (A) came out with quarterly earnings of $1.27 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.13 per share a year ago.

Agilent Technologies (A) Meets Q2 Earnings Estimates

Shares of Agilent Technologies Inc. A, -0.35% fell after hours on Tuesday after the laboratory-equipment maker cut its full-year outlook to reflect “increased market uncertainties” and issued a weaker-than-expected third-quarter forecast. The company said it expected full-year sales of $6.93 billion to $7.03 billion, compared to a prior forecast of $7.03 billion to $7.1 billion given in February.

Agilent shares fall after ‘increased market uncertainties' weigh on outlook

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a core(1) basis. Second-quarter GAAP net income was $302 million, or $1.02 per share. This compares with $274 million, or 91 cents per share, in the second quarter of fiscal year 2022. Non-GAAP(2) net income was $377 million, or $1.27 per share during the quarter, c.

Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session. Jefferies Global Healthcare Conference Mike McMullen, Agilent President and CEO Wednesday, June 7 9:00 – 9:25 a.m. ET / 6:00 – 6:25 a.m. PT Goldman Sachs 44th Annual Global Healthcare Conference Bob McMahon, Agilent CFO Tuesday, June 13 1:00 – 1:40 p.m. ET / 10.

Agilent to Present at Jefferies and Goldman Sachs Healthcare Conferences

Agilent's (A) results for the fiscal second quarter are expected to reflect strength across the LSAG, ACG and DGG segments.

Agilent Technologies (A) to Post Q2 Earnings: What's in Store?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board's (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO's original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA. Agilent resp.

Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents

Agilent (A) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Agilent (A)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today received a SEAL Business Sustainability Award for producing products and technology that are helping analytical and clinical labs reduce their carbon footprint. “Agilent is extremely pleased to receive this recognition,” said Neil Rees, head of Agilent's ESG programs. “We are committed to helping our customers meet their sustainability goals and successfully transition to a low carbon future. Our innovative suite of.

Agilent Wins SEAL Award for Innovative Products that Help Customers Achieve Their Sustainability Goals

Agilent (A) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agilent Technologies (A) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

After losing some value lately, a hammer chart pattern has been formed for Agilent (A), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Agilent (A) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Dr. Jiangbin Ye has received an Agilent Solutions Innovation Research Award (SIRA). The award supports drug discovery and development, research exploration, enhancement, and acceleration. Dr. Ye is an Assistant Professor of Radiation Oncology, within the Division of Radiation and Cancer Biology, at Stanford Medicine, one of seven schools that make up Stanford University. A characteristic of cancer is.

Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye

Amphenol

Danaher

Corning

Keysight

QUALCOMM

Waters

Jefferies analyst Desh Peramunetilleke says cheap stocks set to benefit from China's rebound include Keysight, Qualcomm, Agilent, Danaher, and Corning.

China-Exposed Stocks Have Rallied, but Bargains Still Exist, Says Analyst

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results and hold an earnings conference call for the second quarter of fiscal year 2023 after the stock market closes on Tuesday, May 23 at 1:30 p.m. PDT. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologi.

Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23

ABM Industries

Agree Realty

American Financial Group

American Financial Group Inc 6 1/4 % Debentures 2014-30.9.54 Subord

Alamo Group

Ally Financial

American Tower

A. O. Smith

Ames National

Bar Harbor Bankshares

Bank of New York Mellon

Bank of Montreal

Bristol-Myers

Bank of Nova Scotia

Brady Corporation

Sierra Bancorp

Camden National

Casey's General Stores

Celanese

City Hld

Clorox

Canadian Imperial Bank of Commerce

Dividend Champion, Contender, And Challenger Highlights: Week Of April 23.

Dividend Champion, Contender, And Challenger Highlights: Week Of April 23

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it will highlight new cell analysis, genomics, digital pathology, and companion diagnostics solutions at the American Association for Cancer Research Annual Meeting, held April 14-19, 2023, in Orlando, Florida. Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023.

Agilent Showcases Comprehensive Cancer Portfolio Solutions at AACR 2023

Agilent Technologies (A) partners with PathAI to deliver an AI-powered CDx assay development solution.

Agilent (A) Boosts Reach to Biopharma Researchers With PathAI

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers.

Agilent Announces NGS Assay for Comprehensive Genomic Profiling (CGP) for Advancing Precision Oncology

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent's assay development expertise and PathAI's algorithm development capabilities.

Agilent and PathAI Partner to Deliver AI-Powered Assay Development Solutions for Biopharma Research and Clinical Applications

Agilent (A) strengthens its Life Sciences and Applied Markets Group segment with the launch of new Cary 3500 Flexible UV-Vis system.

News for Agilent Technologies Stock (A)